$EXEL: Exelixis Reports Q3 2026 Revenues of $658.7M and Non-GAAP EPS of $0.94

$EXEL

$EXEL – Exelixis Reports Q3 2026 Revenues of $658.7M and Non-GAAP EPS of $0.94

EXELIXIS, INC.

2026-10-29 00:00:00 UTC · SEC_8K · All $EXEL

?? Positive AI Sentiment (+3.0 / 10)

Total revenues reached $658.7M, driven by $604.9M in Cabozantinib net product sales.
GAAP diluted EPS was $0.85 (up from $0.69 YoY); Non-GAAP diluted EPS reached $0.94.
Full-year revenue guidance maintained at $2.50B–$2.55B, with effective tax rate lowered to 16%–18%.